Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7413609 | 0.81 | PDGFRB (0.54) | MAOBPDGFRBPDGFRAP4HTM | |
| SCHEMBL28652239 | 0.81 | PDGFRB (0.50) | MAOBPDGFRBPDGFRAP4HTM | |
| SCHEMBL1330323 | 0.81 | MAOB (0.50) | MAOBPDGFRBPDGFRAP4HTM | |
| SCHEMBL2142663 | 0.81 | PDGFRB (0.47) | MAOBPDGFRBPDGFRAP4HTM | |
| SCHEMBL7592901 | 0.79 | AKT1 (0.51) | — | |
| SCHEMBL4658454 | 0.79 | HPGD (0.40) | — | |
| SCHEMBL4659642 | 0.79 | — | — | |
| SCHEMBL4659639 | 0.79 | — | — | |
| SCHEMBL7592898 | 0.79 | AKT1 (0.51) | — | |
| SCHEMBL19691724 | 0.78 | PDGFRB (0.51) | MAOBPDGFRBPDGFRAP4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078122-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4673436-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024179948-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-09-06 | — | — | WO | disclosed |
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-1720855-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
| EP-1720855-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005085227-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078122-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | PKN3, PKMYT1, IP6K3 | MAOB 3624/4885PDGFRB 1276/4885PDGFRA 1123/4885 |
| US-20070185152-A1 | Inhibitors of akt activity | AKT1, AKT1S1, AKT2 | MAOB 3018/4885PDGFRB 1037/4885PDGFRA 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.